Ubiquitin-like protein modifiers and their potential for antiviral and anti-HCV therapy

References

• Hochstrasser M. Origin and function of ubiquitin-like proteins. Nature 458(7237), 422–429 (2009).
   PubMed Web of Science ®Google Scholar
• Peng J, Schwartz D, Elias JE et al. A proteomics approach to understanding protein ubiquitination. Nat. Biotechnol. 21(8), 921–926 (2003).
   PubMed Web of Science ®Google Scholar
• Chastagner P, Israël A, Brou C. Itch/AIP4 mediates Deltex degradation through the formation of K29-linked polyubiquitin chains. EMBO Rep. 7(11), 1147–1153 (2006).
   PubMedGoogle Scholar
• Xu G, Paige JS, Jaffrey SR. Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling. Nat. Biotechnol. 28(8), 868–873 (2010).
   PubMed Web of Science ®Google Scholar
• Randow F, Lehner PJ. Viral avoidance and exploitation of the ubiquitin system. Nat. Cell Biol. 11(5), 527–534 (2009).
   PubMed Web of Science ®Google Scholar
• Delboy MG, Roller DG, Nicola AV. Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step. J. Virol. 82(7), 3381–3390 (2008).
   Google Scholar
• Narasimhan J, Wang M, Fu Z, Klein JM, Haas AL, Kim JJ. Crystal structure of the interferon-induced ubiquitin-like protein ISG15. J. Biol. Chem. 280(29), 27356–27365 (2005).
   PubMedGoogle Scholar
• Zhao C, Beaudenon SL, Kelley ML et al. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc. Natl Acad. Sci. USA 101(20), 7578–7582 (2004).
   PubMedGoogle Scholar
• Okumura F, Zou W, Zhang DE. ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev. 21(3), 255–260 (2007).
   PubMed Web of Science ®Google Scholar
• Wong JJ, Pung YF, Sze NS, Chin KC. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc. Natl Acad. Sci. USA 103(28), 10735–10740 (2006).
   PubMed Web of Science ®Google Scholar
• Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J. Biol. Chem. 277(12), 9976–9981 (2002).
   PubMed Web of Science ®Google Scholar
• Shi HX, Yang K, Liu X et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol. Cell. Biol. 30(10), 2424–2436 (2010).
   PubMed Web of Science ®Google Scholar
• Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC, Zhang DE. High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J. Biol. Chem. 278(19), 16608–16613 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang DE. Interferon-stimulated gene 15 and the protein ISGylation system. J. Interferon Cytokine Res. 31(1), 119–130 (2011).
   PubMedGoogle Scholar
• Dao CT, Zhang DE. ISG15: a ubiquitin-like enigma. Front. Biosci. 10, 2701–2722 (2005).
   PubMedGoogle Scholar
• Rosas-Acosta G, Russell WK, Deyrieux A, Russell DH, Wilson VG. A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol. Cell Proteomics 4(1), 56–72 (2005).
   PubMed Web of Science ®Google Scholar
• Bettermann K, Benesch M, Weis S, Haybaeck J. SUMOylation in carcinogenesis. Cancer Lett. 316(2), 113–125 (2012).
   Google Scholar
• Wimmer P, Schreiner S, Dobner T. Human pathogens and the host cell SUMOylation system. J. Virol. 86(2), 642–654 (2012).
   PubMed Web of Science ®Google Scholar
• Kerscher O. SUMO junction – what’s your function? New insights through SUMO-interacting motifs. EMBO Rep. 8(6), 550–555 (2007).
   PubMed Web of Science ®Google Scholar
• Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc. Natl Acad. Sci. USA 101(40), 14373–14378 (2004).
   PubMed Web of Science ®Google Scholar
• Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88(1), 97–107 (1997).
   PubMed Web of Science ®Google Scholar
• Rosas-Acosta G, Russell WK, Deyrieux A, Russell DH, Wilson VG. A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol. Cell Proteomics 4(1), 56–72 (2005).
   PubMed Web of Science ®Google Scholar
• Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11(12), 861–871 (2010).
   PubMed Web of Science ®Google Scholar
• Ribet D, Cossart P. Pathogen-mediated posttranslational modifications: a re-emerging field. Cell 143(5), 694–702 (2010).
   PubMed Web of Science ®Google Scholar
• Isaacson MK, Ploegh HL. Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe 5(6), 559–570 (2009).
   PubMed Web of Science ®Google Scholar
• Rabut G, Peter M. Function and regulation of protein neddylation. ‘Protein modifications: beyond the usual suspects’ review series. EMBO Rep. 9(10), 969–976 (2008).
   PubMed Web of Science ®Google Scholar
• Deshaies RJ, Emberley ED, Saha A. Control of cullin-ring ubiquitin ligase activity by Nedd8. Subcell. Biochem. 54, 41–56 (2010).
   Google Scholar
• Soucy TA, Smith PG, Milhollen MA et al. An inhibitor of Nedd8-activating enzyme as a new approach to treat cancer. Nature 458(7239), 732–736 (2009).
   PubMed Web of Science ®Google Scholar
• Stanley DJ, Bartholomeeusen K, Crosby DC et al. Inhibition of a Nedd8 cascade restores restriction of HIV by APOBEC3G. PLoS Pathog. 8(12), e1003085 (2012).
   Google Scholar
• Schlieker C, Korbel GA, Kattenhorn LM, Ploegh HL. A deubiquitinating activity is conserved in the large tegument protein of the herpesviridae. J. Virol. 79(24), 15582–15585 (2005).
   PubMed Web of Science ®Google Scholar
• Pelzer C, Groettrup M. FAT10: activated by UBA6 and functioning in protein degradation. Subcell. Biochem. 54, 238–246 (2010).
   Google Scholar
• Chiu YH, Sun Q, Chen ZJ. E1-L2 activates both ubiquitin and FAT10. Mol. Cell 27(6), 1014–1023 (2007).
   PubMedGoogle Scholar
• Gong P, Canaan A, Wang B et al. The ubiquitin-like protein FAT10 mediates NF-kappaB activation. J. Am. Soc. Nephrol. 21(2), 316–326 (2010).
   Google Scholar
• Raasi S, Schmidtke G, de Giuli R, Groettrup M. A ubiquitin-like protein which is synergistically inducible by interferon-gamma and tumor necrosis factor-alpha. Eur. J. Immunol. 29(12), 4030–4036 (1999).
   PubMedGoogle Scholar
• Jeram SM, Srikumar T, Pedrioli PG, Raught B. Using mass spectrometry to identify ubiquitin and ubiquitin-like protein conjugation sites. Proteomics 9(4), 922–934 (2009).
   PubMedGoogle Scholar
• Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat. Rev. Mol. Cell Biol. 6, 599–609 (2005).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Yamaguchi S. The ubiquitin-like protein MNSFbeta regulates ERK–MAPK cascade. J. Biol. Chem. 281, 16861–16869 (2006).
   Google Scholar
• Kondoh T, Nakamura M, Nabika T, Yoshimura Y, Tanigawa Y. Ubiquitin-like polypeptide inhibits the proliferative response of T cells in vivo. Immunobiology 200(1), 140–149 (1999).
   Google Scholar
• Komatsu M, Chiba T, Tatsumi K et al. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 23(9), 1977–1986 (2004).
   PubMed Web of Science ®Google Scholar
• Sasakawa H, Sakata E, Yamaguchi Y et al. Solution structure and dynamics of Ufm1, a ubiquitin-fold modifier 1. Biochem. Biophys. Res. Commun. 343(1), 21–26 (2006).
   PubMed Web of Science ®Google Scholar
• Tatsumi K, Sou YS, Tada N et al. A novel type of E3 ligase for the Ufm1 conjugation system. J. Biol. Chem. 285(8), 5417–5427 (2010).
   PubMed Web of Science ®Google Scholar
• Tatsumi K, Yamamoto-Mukai H, Shimizu R et al. The Ufm1-activating enzyme Uba5 is indispensable for erythroid differentiation in mice. Nat. Commun. 2, 181 (2011).
   PubMed Web of Science ®Google Scholar
• Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 469(7330), 323–335 (2011).
   PubMed Web of Science ®Google Scholar
• Geng J, Klionsky DJ. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. ‘Protein modifications: beyond the usual suspects’ review series. EMBO Rep. 9(9), 859–864 (2008).
   PubMed Web of Science ®Google Scholar
• Hwang S, Maloney NS, Bruinsma MW et al. Nondegradative role of Atg5-Atg12/ Atg16L1 autophagy protein complex in antiviral activity of interferon gamma. Cell Host Microbe 11(4), 397–409 (2012).
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang J, Wang L et al. Solution structure of Urm1 and its implications for the origin of protein modifiers. Proc. Natl Acad. Sci. USA 103(31), 11625–11630 (2006).
   PubMed Web of Science ®Google Scholar
• Leidel S, Pedrioli PG, Bucher T et al. Ubiquitin-related modifier Urm1 acts as a sulphur carrier in thiolation of eukaryotic transfer RNA. Nature 458(7235), 228–232 (2009).
   PubMed Web of Science ®Google Scholar
• Van der Veen AG, Schorpp K, Schlieker C et al. Role of the ubiquitin-like proteinUrm1 as a noncanonical lysine-directed protein modifier. Proc. Natl Acad. Sci. USA 108, 1763–1770 (2011).
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13(17), 2436–2441 (2007).
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902), 359–362 (1989).
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125(1), 80–88 (2003).
   PubMed Web of Science ®Google Scholar
• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5(9), 558–567 (2005).
   PubMed Web of Science ®Google Scholar
• Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res. 69(3), 129–141 (2006).
   PubMed Web of Science ®Google Scholar
• Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 282(5390), 938–941 (1998).
   PubMed Web of Science ®Google Scholar
• Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21(19), 5017–5025 (2002).
   PubMed Web of Science ®Google Scholar
• Evans MJ, von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137), 801–805 (2007).
   PubMed Web of Science ®Google Scholar
• Ploss A, Evans MJ, Gaysinskaya VA et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457(7231), 882–886 (2009).
   PubMed Web of Science ®Google Scholar
• Pöhlmann S, Zhang J, Baribaud F et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 77(7), 4070–4080 (2003).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436(7053), 967–972 (2005).
   PubMed Web of Science ®Google Scholar
• Randall G, Panis M, Cooper JD et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl Acad. Sci. USA 104(31), 12884–12889 (2007).
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195–1206 (2011).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S et al.; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364(25), 2417–2428 (2011).
   PubMed Web of Science ®Google Scholar
• Margeridon S, Le Pogam S, Liu TF et al. No detection of variants bearing NS5B S282T mericitabine (MCB) resistance mutation in DAA treatment-naive HCV genotype 1-infected patients using ultra-deep pyrosequencing (UDPS). Presented at: 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, USA, 6–9 November 2011.
   Google Scholar
• Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 32(Suppl. 1), 88–102 (2012).
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu. Rev. Pharmacol. Toxicol. 53, 427–449 (2013).
   PubMed Web of Science ®Google Scholar
• Hopkins S, Gallay P. Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection. Viruses 4(11), 2558–2577 (2012).
   PubMed Web of Science ®Google Scholar
• Kumura G, Lu I, Pitha-Rowe I, Pitha PM. Innate antiviral response targets HIV-1 release by the inducion of ubiquitin-like protein ISG15. Proc. Natl Acad. Sci. USA 103, 1440–1445 (2006).
   Google Scholar
• Ma XZ, Bartczak A, Zhang J et al. Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome. J. Virol. 84(23), 12419–12428 (2010).
   Google Scholar
• Luo H, Zhang J, Cheung C, Suarez A, McManus BM, Yang D. Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am. J. Pathol. 163(2), 381–385 (2003).
   PubMed Web of Science ®Google Scholar
• Ulane CM, Horvath CM. Paramyxoviruses SV5 and HPIV2 assemble STAT protein ubiquitin ligase complexes from cellular components. Virology 304(2), 160–166 (2002).
   PubMedGoogle Scholar
• Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84, 769–779 (1996).
   PubMed Web of Science ®Google Scholar
• Rosas-Acosta G, Wilson VG. Viruses and SUMOylation. In SUMOylation: Molecular Biology and Biochemistry. Wilson VG (Ed.). Horizon Bioscience, Wymondham, UK, 331–377 (2004).
   Google Scholar
• Parkinson J, Everett RD. Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins. J. Virol. 74(21), 10006–10017 (2000).
   PubMedGoogle Scholar
• Gurer C, Berthoux L, Luban J. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J. Virol. 79(2), 910–917 (2005).
   PubMed Web of Science ®Google Scholar
• Zamborlini A, Coiffic A, Beauclair G et al. Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect. J. Biol. Chem. 286(23), 21013–21022 (2011).
   Google Scholar
• Yousef AF, Fonseca GJ, Pelka P et al. Identification of a molecular recognition featurein the E1A oncoprotein that binds theSUMOconjugase UBC9 and likely interferes with polySUMOylation. Oncogene 29, 4693–4704 (2010).
   Google Scholar
• Frisch SM, Mymryk JS. Adenovirus-5 E1A: paradox and paradigm. Nat. Rev. Mol. Cell Biol. 3(6), 441–452 (2002).
   PubMed Web of Science ®Google Scholar
• Endter C, Kzhyshkowska J, Stauber R, Dobner T. SUMO-1 modification required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein. Proc. Natl Acad. Sci. USA 98(20), 11312–11317 (2001).
   PubMedGoogle Scholar
• Pennella MA, Liu Y, Woo JL, Kim CA, Berk AJ. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies. J. Virol. 84(23), 12210–12225 (2010).
   PubMedGoogle Scholar
• Cuchet-Lourenço D, Boutell C, Lukashchuk V et al. SUMO pathway dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog. 7(7), e1002123 (2011).
   Google Scholar
• Maul GG, Everett RD. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0. J. Gen. Virol. 75(Pt 6), 1223–1233 (1994).
   PubMedGoogle Scholar
• Rangasamy D, Wilson VG. Bovine papillomavirus E1 protein is SUMOylated by the host cell Ubc9 protein. J. Biol. Chem. 275, 30487–30495 (2000).
   PubMedGoogle Scholar
• Yasugi T, Vidal M, Sakai H, Howley PM, Benson JD. Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins. J. Virol. 71(8), 5942–5951 (1997).
   Google Scholar
• Kaukinen P, Vaheri A, Plyusnin A. Non-covalent interaction between nucleocapsid protein of Tula hantavirus and small ubiquitin-related modifier-1, SUMO-1. Virus Res. 92(1), 37–45 (2003).
   Google Scholar
• Weldon RA Jr, Sarkar P, Brown SM, Weldon SK. Mason-Pfizer monkey virus Gag proteins interact with the human sumo conjugating enzyme, hUbc9. Virology 314(1), 62–73 (2003).
   PubMed Web of Science ®Google Scholar
• Chang TH, Kubota T, Matsuoka M et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 5(6), e1000493 (2009).
   PubMed Web of Science ®Google Scholar
• Li SJ, Hochstrasser M. A new protease required for cell-cycle progression in yeast. Nature 398(6724), 246–251 (1999).
   PubMed Web of Science ®Google Scholar
• Andrés G, Alejo A, Simón-Mateo C, Salas ML. African swine fever virus protease, a new viral member of the SUMO-1-specific protease family. J. Biol. Chem. 276(1), 780–787 (2001).
   PubMed Web of Science ®Google Scholar
• Ritchie KJ, Hahn CS, Kim KI et al. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat. Med. 10(12), 1374–1378 (2004).
   PubMed Web of Science ®Google Scholar
• Yuan W, Krug RM. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 20(3), 362–371 (2001).
   PubMedGoogle Scholar
• Furman MH, Ploegh HL. Lessons from viral manipulation of protein disposal pathways. J. Clin. Invest. 110(7), 875–879 (2002).
   Google Scholar
• Lenschow DJ, Giannakopoulos NV, Gunn LJ et al. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J. Virol. 79(22), 13974–13983 (2005).
   PubMed Web of Science ®Google Scholar
• Reinert JT, Pitha-Rowe I, Lu G et al. ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. Cell Mol. Biol. 52, 29–41 (2006).
   Google Scholar
• Durfee LA, Lyon N, Seo K, Huibregtse JM. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol. Cell 38(5), 722–732 (2010).
   PubMedGoogle Scholar
• Recht M, Borden EC, Knight E Jr. A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J. Immunol. 147(8), 2617–2623 (1991).
   PubMed Web of Science ®Google Scholar
• Ritchie KJ, Malakhov MP, Hetherington CJ et al. Dysregulation of protein modification by ISG15 results in brain cell injury. Genes Dev. 16(17), 2207–2212 (2002).
   PubMedGoogle Scholar
• Osiak A, Utermöhlen O, Niendorf S, Horak I, Knobeloch KP. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol. Cell. Biol. 25(15), 6338–6345 (2005).
   PubMedGoogle Scholar
• Lenschow DJ, Lai C, Frias-Staheli N et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl Acad. Sci. USA 104(4), 1371–1376 (2007).
   PubMed Web of Science ®Google Scholar
• Knobeloch KP, Utermöhlen O, Kisser A, Prinz M, Horak I. Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of UBP43-deficient mice. Mol. Cell. Biol. 25(24), 11030–11034 (2005).
   PubMedGoogle Scholar
• Kim MJ, Hwang SY, Imaizumi T, Yoo JY. Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. J. Virol. 82(3), 1474–1483 (2008).
   PubMed Web of Science ®Google Scholar
• Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J. Gen. Virol. 91(Pt 2), 382–388 (2010).
   Google Scholar
• Broering R, Zhang X, Kottilil S et al. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut 59(8), 1111–1119 (2010).
   Google Scholar
• Jones DM, Domingues P, Targett-Adams P, McLauchlan J. Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. J. Gen. Virol. 91(Pt 9), 2238–2248 (2010).
   PubMedGoogle Scholar
• Kim MJ, Yoo JY. Inhibition of hepatitis C virus replication by IFN-mediated ISGylation of HCV-NS5A. J. Immunol. 185(7), 4311–4318 (2010).
   Google Scholar
• Ahlquist P. RNA-dependent RNA polymerases, viruses, and RNA silencing. Science 296(5571), 1270–1273 (2002).
   PubMed Web of Science ®Google Scholar
• Banerjee R, Weidman MK, Echeverri A, Kundu P, Dasgupta A. Regulation of poliovirus 3C protease by the 2C polypeptide. J. Virol. 78(17), 9243–9256 (2004).
   Google Scholar
• Kerkvliet J, Zoecklein L, Papke L et al. Transgenic expression of the 3D polymerase inhibits Theiler’s virus infection and demyelination. J. Virol. 83(23), 12279–12289 (2009).
   Google Scholar
• Losick VP, Schlax PE, Emmons RA, Lawson TG. Signals in hepatitis A virus P3 region proteins recognized by the ubiquitin-mediated proteolytic system. Virology 309(2), 306–319 (2003).
   Google Scholar
• Gao L, Tu H, Shi ST et al. Interaction with a ubiquitin-like protein enhances the ubiquitination and degradation of hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77(7), 4149–4159 (2003).
   PubMedGoogle Scholar
• Welbourn S, Green R, Gamache I et al. Hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication. J. Biol. Chem. 280(33), 29604–29611 (2005).
   PubMed Web of Science ®Google Scholar
• Khaliq S, Jahan S, Pervaiz A. Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production. Emer. Infect. Dis. 11(3), 543–556 (2011).
   Google Scholar
• Shirakura M, Murakami K, Ichimura T et al. E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. J. Virol. 81(3), 1174–1185 (2007).
   PubMed Web of Science ®Google Scholar
• Yuksek K, Chen WL, Chien D, Ou JH. Ubiquitin-independent degradation of hepatitis C virus F protein. J. Virol. 83(2), 612–621 (2009).
   Google Scholar
• Chen L, Borozan I, Feld J et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128(5), 1437–1444 (2005).
   PubMed Web of Science ®Google Scholar
• Randall G, Chen L, Panis M et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131(5), 1584–1591 (2006).
   PubMed Web of Science ®Google Scholar
• Chen L, Li S, McGilvray I. The ISG15/USP18 ubiquitin-like pathway (ISGylation system) in hepatitis C virus infection and resistance to interferon therapy. Int. J. Biochem. Cell Biol. 43(10), 1427–1431 (2011).
   Google Scholar
• Xiao C, Qin B, Chen L, Liu H, Zhu Y, Lu X. Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus. J. Viral Hepat. 19(2), e1–e10 (2012).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qin B, Xiao C, Lu X, Chen L. Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic HBV infected patients. Dig. Dis. Sci. 57(9), 2355–2361 (2012).
   Google Scholar
• Gale M Jr, Sen GC. Viral evasion of the interferon system. J. Interferon Cytokine Res. 29(9), 475–476 (2009).
   PubMed Web of Science ®Google Scholar